Test BackgroundCA 15-3 is a high molecular weight (300-450 kDa) transmembrane glycoprotein encoded by the MUC1 gene. It is defined by reactivity with 2 monoclonal antibodies, DF3 and 115D8. CA 15-3 is expressed predominantly in breast cancer (raised in 30 % of localised disease, 75 % metastatic), though primary tumours of the lung, colon, pancreas, liver and endometrium may also give rise to elevations of CA 15-3. Elevations of CA 15-3 values have been reported in individuals with non-malignant conditions such as cirrhosis, hepatitis, autoimmune disorders and benign diseases of the ovary and breast. While increasing CA 15-3 can be the earliest sign of metastatic disease in ~70 % patients, there is little evidence showing that early diagnosis of progressive disease positively impacts survival or quality of life.
Clinical Indications Breast cancer
Sample Required Serum (red top) preferred, SST (gold top) accepted
Sample Volume 0.5 mL
Turnaround Time 4 days
NotesAbbott Architect assay